EPO Patents = 1

Forward Citations = 0

Loading Chart...

6 inventors (with patents filed for the assignee):

Josep Bassaganya-Riera (5 out of 38 patents)

Raquel Hontecillas (5 out of 31 patents)

Andrew Leber (4 out of 16 patents)

4. Adria Carbo Barrios (1 out of 9 patents)

5. Richard Gandour (1 out of 12 patents)

6. Julian D Cooper (1 out of 12 patents)

5 patents: Sort by Forward Citations

1. 12502388 - Lanthionine synthetase C-like 2-based therapeutics (2025-12-23),

2. 12391673 - LANCL ligands (2025-08-19),

3. 12281096 - Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone) (2025-04-21),

4. 12150961 - Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith (2024-11-26),

5. 12145920 - Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same (2024-11-19),

Company Overview

Nimmune Biopharma, Inc. is a biotechnology company focused on developing innovative therapies for autoimmune diseases and cancer. The company leverages advanced immunotherapy techniques to create targeted treatments that aim to modulate the immune system. With a commitment to scientific excellence and patient-centric solutions, Nimmune is dedicated to improving the quality of life for patients through groundbreaking research and development. Their pipeline includes several promising candidates that are currently in various stages of clinical trials, showcasing their potential to address unmet medical needs in the therapeutic landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

5 Patents

#22 in Blacksburg, VA

#925 in Virginia

#51,644 in US

Blacksburg, VA, United States of America

Nimmune Biopharma, Inc.

Forward Citations = 0

6 inventors:

Josep Bassaganya-Riera (5 out of 38 patents)

Raquel Hontecillas (5 out of 31 patents)

Andrew Leber (4 out of 16 patents)

4. Adria Carbo Barrios (1 out of 9 patents)

5. Richard Gandour (1 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nimmune Biopharma, Inc.. Retrieved from https://idiyas.com/company/nimmune-biopharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]